H.C. Wainwright Starts vTv Therapeutics (VTVT) at Buy

September 26, 2016 7:37 AM EDT
Get Alerts VTVT Hot Sheet
Price: $5.39 --0%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade VTVT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

H.C. Wainwright initiates coverage on vTv Therapeutics (NASDAQ: VTVT) with a Buy rating and a price target of $13.00.

Analyst Corey Davis commented, "Although much of the Street is focused on Azeliragon, in mild Alzheimer’s’ disease (AD), we find the diabetes compounds to be more likely to move the stock in the near-term. Azeliragon has completed enrollment in the first Phase 3 study (second now enrolling), and with data expected in early 2018, it could be one of the next wave of promising Alzheimer's drugs, an area that is littered with drug failures for the industry. Therefore, given the history and lack of data until 2018, we don't see the stock trading on this anytime soon. We are more enthusiastic about the two diabetes drugs that should be ripe for partnering upon success in Phase 2. TTP399 completed a successful Phase 2b in August and TTP273 should have Phase 2b data in December, the nearest term catalyst."

  • TTP399 would be the first "selective" GKA.
  • TTP273 would be one of the first oral GLP1's.
  • Azeliragon's novel mechanism.
  • Upcoming potential stock moving catalysts include: (see full report)
  • Our target of $13 would only be a $425M market cap.

For an analyst ratings summary and ratings history on vTv Therapeutics click here. For more ratings news on vTv Therapeutics click here.

Shares of vTv Therapeutics closed at $7.17 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment